[go: up one dir, main page]

DE60026644D1 - Verwendung von Ferulasäure zur Behandlung von Bluthochdruck - Google Patents

Verwendung von Ferulasäure zur Behandlung von Bluthochdruck

Info

Publication number
DE60026644D1
DE60026644D1 DE60026644T DE60026644T DE60026644D1 DE 60026644 D1 DE60026644 D1 DE 60026644D1 DE 60026644 T DE60026644 T DE 60026644T DE 60026644 T DE60026644 T DE 60026644T DE 60026644 D1 DE60026644 D1 DE 60026644D1
Authority
DE
Germany
Prior art keywords
hypertension
treatment
ferulic acid
ferulic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026644T
Other languages
English (en)
Other versions
DE60026644T2 (de
Inventor
Atsushi Suzuki
Ryuji Ochiai
Ichiro Tokimitsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2000230463A external-priority patent/JP4234888B2/ja
Application filed by Kao Corp filed Critical Kao Corp
Publication of DE60026644D1 publication Critical patent/DE60026644D1/de
Application granted granted Critical
Publication of DE60026644T2 publication Critical patent/DE60026644T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60026644T 1999-09-22 2000-09-22 Verwendung von Ferulasäure zur Behandlung von Bluthochdruck Expired - Lifetime DE60026644T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP26846199 1999-09-22
JP26846199 1999-09-22
JP2000230463 2000-07-31
JP2000230463A JP4234888B2 (ja) 1999-09-22 2000-07-31 高血圧症予防・治療剤

Publications (2)

Publication Number Publication Date
DE60026644D1 true DE60026644D1 (de) 2006-05-11
DE60026644T2 DE60026644T2 (de) 2006-11-09

Family

ID=26548321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026644T Expired - Lifetime DE60026644T2 (de) 1999-09-22 2000-09-22 Verwendung von Ferulasäure zur Behandlung von Bluthochdruck

Country Status (4)

Country Link
US (1) US6310100B1 (de)
EP (1) EP1090635B1 (de)
DE (1) DE60026644T2 (de)
ES (1) ES2259589T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3548102B2 (ja) * 2000-08-07 2004-07-28 花王株式会社 高血圧症予防・治療剤
US6991812B2 (en) * 2000-09-05 2006-01-31 Kao Corporation Agent for preventing, improving or treating hypertension
JP2002363075A (ja) 2001-06-05 2002-12-18 Kao Corp 高血圧症予防・治療剤
JP4119629B2 (ja) * 2001-09-06 2008-07-16 花王株式会社 高血圧症予防・改善・治療剤
US20040101545A1 (en) * 2002-11-26 2004-05-27 Schoenherr William D. Composition and method
EP1602372B1 (de) * 2003-02-07 2016-08-31 Mochida Pharmaceutical Co., Ltd. Arzneimittel zur besseren prognose für subarachnoide blutung
US20040156924A1 (en) * 2003-02-10 2004-08-12 Jonathan Selzer Vitamin C and calcium ascorbate based dietary supplement products
CA2662710A1 (en) * 2006-09-07 2008-03-13 Mcgill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
MX370090B (es) 2013-02-01 2019-10-25 Centro De Investig En Alimentacion Y Desarrollo A C Un método y un sistema para el tratamiento integral de aguas residuales de una industria del maíz.
TWI532482B (zh) * 2014-09-01 2016-05-11 國立中山大學 阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
US11252975B2 (en) 2017-09-29 2022-02-22 Societe Des Produits Nestle S.A. Caffeine production method
CN111088297B (zh) * 2019-12-26 2022-04-08 广州市幕之时实业有限公司 一种酶法制备脂肪酰胺的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58150600A (ja) * 1982-03-02 1983-09-07 Tomotaro Tsuchiya オリザノ−ルの１成分２４メチレンシクロアルタノ−ルフエルラ酸エステルの油溶性又は乳化性の溶液化又は固型化法
JPS6140298A (ja) * 1984-06-30 1986-02-26 Zeria Shinyaku Kogyo Kk シクロアルテノ−ルフエルラ酸エステル−シクロデキストリン複合体
JPS61194022A (ja) * 1985-02-23 1986-08-28 Zeria Shinyaku Kogyo Kk シクロアルテノ−ルフエルラ酸エステル−ポリビニルピロリドン共沈体
US5108750A (en) * 1986-09-08 1992-04-28 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
JPH0778032B2 (ja) * 1991-03-13 1995-08-23 和歌山県 フェルラ酸の製造方法
BR9608914A (pt) * 1995-06-01 1999-03-02 Unilever Nv Produto alimentício á base de gorgura pasta de gordura amarela e uso de um concentrado oleoso
DE69612011T3 (de) * 1995-11-24 2010-02-18 Unilever N.V. Zusammensetzung auf basis von fischöl
US6139897A (en) 1998-03-24 2000-10-31 Kao Corporation Oil or fat composition containing phytosterol
US6025348A (en) 1998-04-30 2000-02-15 Kao Corporation Oil and fat composition containing phytosterol
WO2000061131A1 (en) * 1999-04-13 2000-10-19 Scigenic Co., Ltd. Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same
JP3589904B2 (ja) * 1999-06-17 2004-11-17 花王株式会社 酸性水中油型乳化組成物

Also Published As

Publication number Publication date
EP1090635A2 (de) 2001-04-11
EP1090635A3 (de) 2002-02-27
ES2259589T3 (es) 2006-10-16
EP1090635B1 (de) 2006-03-15
DE60026644T2 (de) 2006-11-09
US6310100B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
ATE524173T1 (de) Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition